Tag: data

Company News: Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen

– Four scientific communications scheduled for June 8, 9 and 10, 2014 –

Anergis, a company discovering and developing proprietary allergy vaccines, today announced it will present four scientific communications on its Contiguous Overlapping Peptides (COP) allergy vaccines at this year’s European Academy of  Allergy and Clinical Immunology Congress 2014 (EAACI) in Copenhagen, Denmark. The presentations focus on Anergis´ lead compound AllerT against birch pollen allergies, its house dust mite vaccine candidate AllerDM, and a general economic evaluation of allergen immunotherapy for seasonal allergies.

The following scientific communications will be presented at the EAACI Conference 2014:

Presentation Title:AllerT™, Safety and efficacy of a birch pollen allergy vaccine based on contiguous overlapping peptides in a phase IIb study”

Presenter: Prof. Dr. Marek Jutel

Time and Date: Sunday, June 8, 2014, at 03:30pm CET

Session: Oral Abstract Session OAS12: Novel Vaccines for AIT

Abstract #: 481

 

Presentation Title:Development of a hypoallergenic formulation for immunotherapy against house dust mite allergy based on Contiguous Overlapping Peptides”

Presenter: Dr. Alexander Kettner

Time and Date: Monday, June 9, 2014, at 03:45pm CET

Session: Poster Discussion Session PDS 12: AIT Mechanisms

Abstract #: 347

 

Presentation Title: “Effect of AllerT™ ultra-fast immunotherapy on Bet v 1 specific IgG4 and IgE levels; results from a phase IIb study”

Presenter: Prof. Dr. Christophe Reymond

Time and Date: Monday, June 9, 2014, at 03:45pm CET

Session: Poster Discussion Session PDS 12: AIT Mechanisms

Abstract #: 559

 

Presentation Title:Economic evaluation of allergen immunotherapy for seasonal allergic rhinitis”

Presenter: Jean-Paul Rohmer

Time and Date: Tuesday, June 10, 2014, at 12:00pm CET

Session: Thematic Poster Session TPS64: Immunotherapy – AIT Clinics IV

Abstract #: 1411

Company News: biocrea’s First-in-class PDE2 Inhibitor Demonstrates Strong Potential For The Treatment Of Cognitive Disorders

– Data on novel PDE2 inhibitor BCA909 presented at 24th ECNP Congress in Paris –

biocrea, a biopharmaceutical company focusing on novel treatments for disorders of the central nervous system (CNS), today announced data on its innovative CNS-penetrating PDE2 inhibitor. The compound, which is code-named BCA909, was selected as a candidate for preclinical development  earlier this year. It demonstrates strong potential for the treatment of diseases in which normal learning and memory is impaired, e.g. mild cognitive impairment, Alzheimer’s disease and schizophrenia. Details on the compound were presented at the 24th ECNP Congress of the European College of Neuropharmacology in Paris, France (Sept. 3-7, 2011).

To date, few PDE2 inhibitors have been pharmacologically characterized. While initial findings have been encouraging, suggesting pro-cognitive and anxiolytic efficacy, the compounds did not enter the brain in sufficient quantities. With BCA909, biocrea has developed a novel, potent and selective PDE2 inhibitor with excellent CNS penetration and an efficacy and safety profile suitable for further development for multiple disease indications.

During the ECNP congress, biocrea presented data from extensive preclinical studies in vitro and in animal models of learning and memory. The key findings demonstrate that BCA909 delivers significant pro-cognitive activity in models of cognitive impairment resulting from either disruption of cholinergic or glutamatergic neurotransmission. Furthermore, BCA909 does not induce tolerance, indicating that maintained pro-cognitive efficacy, achieved through modulation of multiple neurotransmitter systems, can be delivered by the novel PDE2 mechanism of action.

Preclinical development of BCA909 is ongoing.